111 related articles for article (PubMed ID: 24669383)
1. Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
Prescrire Int; 2014 Feb; 23(146):40-1. PubMed ID: 24669383
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone and increased survival in metastatic prostate cancer.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
[No Abstract] [Full Text] [Related]
3. Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G
N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
[No Abstract] [Full Text] [Related]
4. Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Prescrire Int; 2012 Jun; 21(128):147-9. PubMed ID: 22822591
[TBL] [Abstract][Full Text] [Related]
5. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
7. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.
Pezaro C; Mukherji D; Tunariu N; Cassidy AM; Omlin A; Bianchini D; Seed G; Reid AH; Olmos D; de Bono JS; Attard G
Br J Cancer; 2013 Jul; 109(2):325-31. PubMed ID: 23807167
[TBL] [Abstract][Full Text] [Related]
8. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
Attard G; Belldegrun AS; de Bono JS
BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
[No Abstract] [Full Text] [Related]
9. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Messina C; Messina M; Boccardo F
Eur Urol; 2018 Jan; 73(1):147-148. PubMed ID: 28801126
[No Abstract] [Full Text] [Related]
10. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
11. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
12. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone and castration-resistant prostate cancer.
Burki TK
Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
[No Abstract] [Full Text] [Related]
15. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.
Prescrire Int; 2013 Mar; 22(136):74-8. PubMed ID: 23593699
[TBL] [Abstract][Full Text] [Related]
17. Expanding treatment options for metastatic prostate cancer.
Antonarakis ES; Eisenberger MA
N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
[No Abstract] [Full Text] [Related]
18. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
19. [New drugs in metastatic castration-resistant prostate cancer].
Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
[TBL] [Abstract][Full Text] [Related]
20. First-line abiraterone improves survival in prostate cancer.
Brower V
Lancet Oncol; 2017 Jul; 18(7):e374. PubMed ID: 28602778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
